SAN DIEGO, June 10 /PRNewswire-FirstCall/ -- Biosite Incorporated
(Nasdaq: BSTE) today announced that Kim Blickenstaff, Biosite's chairman and
chief executive officer and Ken Buechler, Ph.D., president and chief
scientific officer, will participate in a question and answer format
discussion at the Thomas Weisel Partners Growth Forum 7.0. The company
anticipates that in their remarks Mr. Blickenstaff and Dr. Buechler will
address the Company's operating environment, business strategy, products under
development and clinical programs. The discussion will take place on
Wednesday, June 15 at 9:10 a.m. Pacific at The Four Seasons Hotel in San
Francisco.
A link to the live audio webcast can be accessed through the Biosite
website, http://www.biosite.com. The Biosite will be archived on the website for
21 days in the Investor and Media section under Events Calendar.
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis. The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions.
Biosite's Triage(R) rapid diagnostics are used in approximately 50 percent of
U.S. hospitals and in over 50 international markets. Information on Biosite
can be found at http://www.biosite.com.
Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated. The Company's logo is a trademark of
Biosite Incorporated.
SOURCE Biosite Incorporated
 back to top
Related links:
http://www.biosite.com
Company News On-Call:
http://www.prnewswire.com/comp/116737.html
CONTACT:
Nadine Padilla, Vice President, Corporate and
Investor Relations of Biosite Incorporated, +1-858-455-4808, ext.
3187, npadilla@biosite.com
|
